nodes	percent_of_prediction	percent_of_DWPC	metapath
Haloperidol—CBR1—Doxorubicin—uterine cancer	0.148	0.215	CbGbCtD
Haloperidol—SIGMAR1—Progesterone—uterine cancer	0.143	0.208	CbGbCtD
Haloperidol—CYP1A1—Progesterone—uterine cancer	0.0506	0.0736	CbGbCtD
Haloperidol—CYP3A7—Progesterone—uterine cancer	0.0405	0.0589	CbGbCtD
Haloperidol—CYP3A7-CYP3A51P—Progesterone—uterine cancer	0.0405	0.0589	CbGbCtD
Haloperidol—CYP2C9—Medroxyprogesterone Acetate—uterine cancer	0.0307	0.0447	CbGbCtD
Haloperidol—CYP3A5—Progesterone—uterine cancer	0.0304	0.0442	CbGbCtD
Haloperidol—CYP2C19—Progesterone—uterine cancer	0.0245	0.0357	CbGbCtD
Haloperidol—CYP1A2—Progesterone—uterine cancer	0.0226	0.0329	CbGbCtD
Haloperidol—CYP2C9—Progesterone—uterine cancer	0.0204	0.0296	CbGbCtD
Haloperidol—ABCB1—Progesterone—uterine cancer	0.0198	0.0288	CbGbCtD
Haloperidol—CYP2D6—Progesterone—uterine cancer	0.0186	0.0271	CbGbCtD
Haloperidol—CYP3A4—Medroxyprogesterone Acetate—uterine cancer	0.0179	0.026	CbGbCtD
Haloperidol—ABCB1—Dactinomycin—uterine cancer	0.0157	0.0228	CbGbCtD
Haloperidol—CYP3A5—Etoposide—uterine cancer	0.0136	0.0198	CbGbCtD
Haloperidol—CYP3A4—Progesterone—uterine cancer	0.0118	0.0172	CbGbCtD
Haloperidol—CYP1A2—Etoposide—uterine cancer	0.0101	0.0147	CbGbCtD
Haloperidol—ABCB1—Etoposide—uterine cancer	0.00884	0.0129	CbGbCtD
Haloperidol—ABCB1—Doxorubicin—uterine cancer	0.00603	0.00878	CbGbCtD
Haloperidol—H1F0—semen—uterine cancer	0.00592	0.0697	CbGeAlD
Haloperidol—CYP2D6—Doxorubicin—uterine cancer	0.00568	0.00827	CbGbCtD
Haloperidol—CYP3A4—Etoposide—uterine cancer	0.0053	0.00771	CbGbCtD
Haloperidol—H1F0—oviduct—uterine cancer	0.00435	0.0511	CbGeAlD
Haloperidol—CYP3A4—Doxorubicin—uterine cancer	0.00361	0.00526	CbGbCtD
Haloperidol—EBP—uterine cervix—uterine cancer	0.0029	0.0341	CbGeAlD
Haloperidol—EBP—uterus—uterine cancer	0.00241	0.0284	CbGeAlD
Haloperidol—HTR1B—artery—uterine cancer	0.0023	0.0271	CbGeAlD
Haloperidol—HTR1D—artery—uterine cancer	0.00223	0.0262	CbGeAlD
Haloperidol—EBP—female reproductive system—uterine cancer	0.00217	0.0255	CbGeAlD
Haloperidol—SIGMAR1—Levonorgestrel—Progesterone—uterine cancer	0.00207	1	CbGdCrCtD
Haloperidol—CBR1—myometrium—uterine cancer	0.0017	0.02	CbGeAlD
Haloperidol—UGT1A9—renal system—uterine cancer	0.00164	0.0193	CbGeAlD
Haloperidol—H1F0—myometrium—uterine cancer	0.00139	0.0164	CbGeAlD
Haloperidol—CBR1—uterine cervix—uterine cancer	0.00132	0.0155	CbGeAlD
Haloperidol—CBR1—decidua—uterine cancer	0.00126	0.0148	CbGeAlD
Haloperidol—CBR1—renal system—uterine cancer	0.00124	0.0145	CbGeAlD
Haloperidol—CBR1—endometrium—uterine cancer	0.00119	0.0141	CbGeAlD
Haloperidol—CBR1—mammalian vulva—uterine cancer	0.00116	0.0136	CbGeAlD
Haloperidol—HTR2A—artery—uterine cancer	0.00111	0.013	CbGeAlD
Haloperidol—CBR1—uterus—uterine cancer	0.0011	0.0129	CbGeAlD
Haloperidol—H1F0—uterine cervix—uterine cancer	0.00108	0.0127	CbGeAlD
Haloperidol—H1F0—smooth muscle tissue—uterine cancer	0.00105	0.0124	CbGeAlD
Haloperidol—H1F0—decidua—uterine cancer	0.00103	0.0121	CbGeAlD
Haloperidol—H1F0—renal system—uterine cancer	0.00101	0.0119	CbGeAlD
Haloperidol—SIGMAR1—myometrium—uterine cancer	0.001	0.0118	CbGeAlD
Haloperidol—HTR2B—myometrium—uterine cancer	0.001	0.0118	CbGeAlD
Haloperidol—CBR1—female reproductive system—uterine cancer	0.000989	0.0116	CbGeAlD
Haloperidol—H1F0—endometrium—uterine cancer	0.000979	0.0115	CbGeAlD
Haloperidol—H1F0—mammalian vulva—uterine cancer	0.000947	0.0111	CbGeAlD
Haloperidol—H1F0—uterus—uterine cancer	0.000902	0.0106	CbGeAlD
Haloperidol—CBR1—female gonad—uterine cancer	0.0009	0.0106	CbGeAlD
Haloperidol—CBR1—vagina—uterine cancer	0.000895	0.0105	CbGeAlD
Haloperidol—H1F0—female reproductive system—uterine cancer	0.000811	0.00954	CbGeAlD
Haloperidol—KCNH2—myometrium—uterine cancer	0.000799	0.0094	CbGeAlD
Haloperidol—SIGMAR1—uterine cervix—uterine cancer	0.000781	0.00919	CbGeAlD
Haloperidol—HTR2B—uterine cervix—uterine cancer	0.00078	0.00917	CbGeAlD
Haloperidol—SIGMAR1—smooth muscle tissue—uterine cancer	0.000759	0.00893	CbGeAlD
Haloperidol—HTR2B—smooth muscle tissue—uterine cancer	0.000758	0.00891	CbGeAlD
Haloperidol—SIGMAR1—decidua—uterine cancer	0.000744	0.00876	CbGeAlD
Haloperidol—HTR2B—decidua—uterine cancer	0.000743	0.00874	CbGeAlD
Haloperidol—H1F0—female gonad—uterine cancer	0.000738	0.00868	CbGeAlD
Haloperidol—H1F0—vagina—uterine cancer	0.000733	0.00862	CbGeAlD
Haloperidol—SIGMAR1—endometrium—uterine cancer	0.000707	0.00831	CbGeAlD
Haloperidol—HTR2B—endometrium—uterine cancer	0.000705	0.0083	CbGeAlD
Haloperidol—SIGMAR1—mammalian vulva—uterine cancer	0.000684	0.00804	CbGeAlD
Haloperidol—SIGMAR1—uterus—uterine cancer	0.000651	0.00766	CbGeAlD
Haloperidol—HTR2B—uterus—uterine cancer	0.00065	0.00764	CbGeAlD
Haloperidol—HTR1B—female reproductive system—uterine cancer	0.000649	0.00763	CbGeAlD
Haloperidol—HRH1—myometrium—uterine cancer	0.000641	0.00754	CbGeAlD
Haloperidol—HTR1D—female reproductive system—uterine cancer	0.000628	0.00739	CbGeAlD
Haloperidol—KCNH2—uterine cervix—uterine cancer	0.000622	0.00732	CbGeAlD
Haloperidol—HTR2B—female reproductive system—uterine cancer	0.000584	0.00687	CbGeAlD
Haloperidol—KCNH2—renal system—uterine cancer	0.000582	0.00684	CbGeAlD
Haloperidol—CBR1—lymph node—uterine cancer	0.000579	0.00681	CbGeAlD
Haloperidol—KCNH2—endometrium—uterine cancer	0.000563	0.00662	CbGeAlD
Haloperidol—SIGMAR1—female gonad—uterine cancer	0.000533	0.00627	CbGeAlD
Haloperidol—CYP1A1—epithelium—uterine cancer	0.00053	0.00623	CbGeAlD
Haloperidol—SIGMAR1—vagina—uterine cancer	0.000529	0.00623	CbGeAlD
Haloperidol—HTR2B—vagina—uterine cancer	0.000528	0.00622	CbGeAlD
Haloperidol—CYP1A1—uterine cervix—uterine cancer	0.000525	0.00618	CbGeAlD
Haloperidol—KCNH2—uterus—uterine cancer	0.000518	0.0061	CbGeAlD
Haloperidol—CYP3A5—uterine cervix—uterine cancer	0.000514	0.00604	CbGeAlD
Haloperidol—HRH1—epithelium—uterine cancer	0.000503	0.00591	CbGeAlD
Haloperidol—HRH1—uterine cervix—uterine cancer	0.000498	0.00586	CbGeAlD
Haloperidol—CYP1A2—renal system—uterine cancer	0.000498	0.00586	CbGeAlD
Haloperidol—CYP1A1—renal system—uterine cancer	0.000491	0.00578	CbGeAlD
Haloperidol—HRH1—smooth muscle tissue—uterine cancer	0.000484	0.0057	CbGeAlD
Haloperidol—CYP3A5—renal system—uterine cancer	0.00048	0.00565	CbGeAlD
Haloperidol—HRH1—decidua—uterine cancer	0.000475	0.00559	CbGeAlD
Haloperidol—H1F0—lymph node—uterine cancer	0.000474	0.00558	CbGeAlD
Haloperidol—KCNH2—female reproductive system—uterine cancer	0.000466	0.00548	CbGeAlD
Haloperidol—CYP1A1—mammalian vulva—uterine cancer	0.00046	0.00541	CbGeAlD
Haloperidol—HRH1—endometrium—uterine cancer	0.000451	0.0053	CbGeAlD
Haloperidol—CYP2C19—vagina—uterine cancer	0.000442	0.0052	CbGeAlD
Haloperidol—CYP1A1—uterus—uterine cancer	0.000438	0.00515	CbGeAlD
Haloperidol—HRH1—mammalian vulva—uterine cancer	0.000436	0.00513	CbGeAlD
Haloperidol—KCNH2—female gonad—uterine cancer	0.000424	0.00499	CbGeAlD
Haloperidol—KCNH2—vagina—uterine cancer	0.000421	0.00496	CbGeAlD
Haloperidol—HTR2A—epithelium—uterine cancer	0.00042	0.00494	CbGeAlD
Haloperidol—HTR2A—smooth muscle tissue—uterine cancer	0.000405	0.00476	CbGeAlD
Haloperidol—CYP1A1—female reproductive system—uterine cancer	0.000394	0.00463	CbGeAlD
Haloperidol—HTR2A—renal system—uterine cancer	0.000389	0.00458	CbGeAlD
Haloperidol—CYP2C9—female reproductive system—uterine cancer	0.000379	0.00446	CbGeAlD
Haloperidol—HRH1—female reproductive system—uterine cancer	0.000373	0.00439	CbGeAlD
Haloperidol—CYP3A4—renal system—uterine cancer	0.000361	0.00424	CbGeAlD
Haloperidol—CYP1A1—female gonad—uterine cancer	0.000358	0.00421	CbGeAlD
Haloperidol—CYP1A1—vagina—uterine cancer	0.000356	0.00419	CbGeAlD
Haloperidol—CYP2D6—renal system—uterine cancer	0.000355	0.00417	CbGeAlD
Haloperidol—ABCB1—myometrium—uterine cancer	0.000351	0.00412	CbGeAlD
Haloperidol—CYP3A5—female gonad—uterine cancer	0.00035	0.00412	CbGeAlD
Haloperidol—CYP3A5—vagina—uterine cancer	0.000348	0.00409	CbGeAlD
Haloperidol—SIGMAR1—lymph node—uterine cancer	0.000342	0.00403	CbGeAlD
Haloperidol—HTR2B—lymph node—uterine cancer	0.000342	0.00402	CbGeAlD
Haloperidol—HRH1—female gonad—uterine cancer	0.00034	0.004	CbGeAlD
Haloperidol—HRH1—vagina—uterine cancer	0.000338	0.00397	CbGeAlD
Haloperidol—Amenorrhoea—Doxorubicin—uterine cancer	0.000336	0.00203	CcSEcCtD
Haloperidol—Neutropenia—Etoposide—uterine cancer	0.000334	0.00201	CcSEcCtD
Haloperidol—Feeling abnormal—Progesterone—uterine cancer	0.000327	0.00197	CcSEcCtD
Haloperidol—Gait disturbance—Epirubicin—uterine cancer	0.000327	0.00197	CcSEcCtD
Haloperidol—Insomnia—Medroxyprogesterone Acetate—uterine cancer	0.000326	0.00196	CcSEcCtD
Haloperidol—Dyspnoea—Medroxyprogesterone Acetate—uterine cancer	0.000321	0.00193	CcSEcCtD
Haloperidol—Somnolence—Medroxyprogesterone Acetate—uterine cancer	0.00032	0.00193	CcSEcCtD
Haloperidol—Ventricular tachycardia—Epirubicin—uterine cancer	0.000319	0.00192	CcSEcCtD
Haloperidol—Anaemia—Dactinomycin—uterine cancer	0.000318	0.00192	CcSEcCtD
Haloperidol—Injection site reaction—Epirubicin—uterine cancer	0.000317	0.00191	CcSEcCtD
Haloperidol—Dyspepsia—Medroxyprogesterone Acetate—uterine cancer	0.000317	0.00191	CcSEcCtD
Haloperidol—Urticaria—Progesterone—uterine cancer	0.000316	0.0019	CcSEcCtD
Haloperidol—Dyskinesia—Doxorubicin—uterine cancer	0.000314	0.00189	CcSEcCtD
Haloperidol—Body temperature increased—Progesterone—uterine cancer	0.000314	0.00189	CcSEcCtD
Haloperidol—Decreased appetite—Medroxyprogesterone Acetate—uterine cancer	0.000313	0.00189	CcSEcCtD
Haloperidol—HTR2A—female reproductive system—uterine cancer	0.000312	0.00367	CbGeAlD
Haloperidol—Gastrointestinal disorder—Medroxyprogesterone Acetate—uterine cancer	0.000311	0.00187	CcSEcCtD
Haloperidol—Jaundice—Etoposide—uterine cancer	0.000311	0.00187	CcSEcCtD
Haloperidol—Salivary hypersecretion—Epirubicin—uterine cancer	0.00031	0.00187	CcSEcCtD
Haloperidol—Leukopenia—Dactinomycin—uterine cancer	0.000308	0.00186	CcSEcCtD
Haloperidol—Constipation—Medroxyprogesterone Acetate—uterine cancer	0.000308	0.00186	CcSEcCtD
Haloperidol—Gait disturbance—Doxorubicin—uterine cancer	0.000303	0.00182	CcSEcCtD
Haloperidol—Hepatobiliary disease—Etoposide—uterine cancer	0.000301	0.00182	CcSEcCtD
Haloperidol—Agranulocytosis—Etoposide—uterine cancer	0.000297	0.00179	CcSEcCtD
Haloperidol—Feeling abnormal—Medroxyprogesterone Acetate—uterine cancer	0.000297	0.00179	CcSEcCtD
Haloperidol—Ventricular tachycardia—Doxorubicin—uterine cancer	0.000295	0.00178	CcSEcCtD
Haloperidol—Injection site reaction—Doxorubicin—uterine cancer	0.000294	0.00177	CcSEcCtD
Haloperidol—Hypersensitivity—Progesterone—uterine cancer	0.000293	0.00176	CcSEcCtD
Haloperidol—CYP3A4—female reproductive system—uterine cancer	0.000289	0.0034	CbGeAlD
Haloperidol—Salivary hypersecretion—Doxorubicin—uterine cancer	0.000287	0.00173	CcSEcCtD
Haloperidol—Urticaria—Medroxyprogesterone Acetate—uterine cancer	0.000286	0.00172	CcSEcCtD
Haloperidol—Body temperature increased—Medroxyprogesterone Acetate—uterine cancer	0.000285	0.00172	CcSEcCtD
Haloperidol—CYP2D6—female reproductive system—uterine cancer	0.000284	0.00334	CbGeAlD
Haloperidol—Urinary tract disorder—Etoposide—uterine cancer	0.000282	0.0017	CcSEcCtD
Haloperidol—HTR2A—vagina—uterine cancer	0.000282	0.00332	CbGeAlD
Haloperidol—Pruritus—Progesterone—uterine cancer	0.000281	0.00169	CcSEcCtD
Haloperidol—Oedema—Dactinomycin—uterine cancer	0.000281	0.00169	CcSEcCtD
Haloperidol—Urethral disorder—Etoposide—uterine cancer	0.00028	0.00169	CcSEcCtD
Haloperidol—Hypertonia—Epirubicin—uterine cancer	0.00028	0.00169	CcSEcCtD
Haloperidol—ABCB1—epithelium—uterine cancer	0.000275	0.00324	CbGeAlD
Haloperidol—Thrombocytopenia—Dactinomycin—uterine cancer	0.000275	0.00166	CcSEcCtD
Haloperidol—ABCB1—uterine cervix—uterine cancer	0.000273	0.00321	CbGeAlD
Haloperidol—KCNH2—lymph node—uterine cancer	0.000273	0.00321	CbGeAlD
Haloperidol—Diarrhoea—Progesterone—uterine cancer	0.000272	0.00164	CcSEcCtD
Haloperidol—Anorexia—Dactinomycin—uterine cancer	0.000268	0.00161	CcSEcCtD
Haloperidol—Eye disorder—Etoposide—uterine cancer	0.000267	0.00161	CcSEcCtD
Haloperidol—Cardiac disorder—Etoposide—uterine cancer	0.000265	0.0016	CcSEcCtD
Haloperidol—Hypersensitivity—Medroxyprogesterone Acetate—uterine cancer	0.000265	0.0016	CcSEcCtD
Haloperidol—Hepatic function abnormal—Epirubicin—uterine cancer	0.000265	0.0016	CcSEcCtD
Haloperidol—Photosensitivity—Epirubicin—uterine cancer	0.000264	0.00159	CcSEcCtD
Haloperidol—Dizziness—Progesterone—uterine cancer	0.000263	0.00158	CcSEcCtD
Haloperidol—ABCB1—decidua—uterine cancer	0.00026	0.00306	CbGeAlD
Haloperidol—Angiopathy—Etoposide—uterine cancer	0.00026	0.00156	CcSEcCtD
Haloperidol—Hypertonia—Doxorubicin—uterine cancer	0.000259	0.00156	CcSEcCtD
Haloperidol—CYP2D6—female gonad—uterine cancer	0.000259	0.00304	CbGeAlD
Haloperidol—Immune system disorder—Etoposide—uterine cancer	0.000258	0.00156	CcSEcCtD
Haloperidol—Mediastinal disorder—Etoposide—uterine cancer	0.000258	0.00155	CcSEcCtD
Haloperidol—ABCB1—renal system—uterine cancer	0.000255	0.003	CbGeAlD
Haloperidol—Pruritus—Medroxyprogesterone Acetate—uterine cancer	0.000255	0.00153	CcSEcCtD
Haloperidol—Alopecia—Etoposide—uterine cancer	0.000253	0.00152	CcSEcCtD
Haloperidol—Vomiting—Progesterone—uterine cancer	0.000253	0.00152	CcSEcCtD
Haloperidol—Rash—Progesterone—uterine cancer	0.00025	0.00151	CcSEcCtD
Haloperidol—Dermatitis—Progesterone—uterine cancer	0.00025	0.00151	CcSEcCtD
Haloperidol—Headache—Progesterone—uterine cancer	0.000249	0.0015	CcSEcCtD
Haloperidol—ABCB1—endometrium—uterine cancer	0.000247	0.0029	CbGeAlD
Haloperidol—Diarrhoea—Medroxyprogesterone Acetate—uterine cancer	0.000246	0.00148	CcSEcCtD
Haloperidol—Dermatitis exfoliative—Epirubicin—uterine cancer	0.000246	0.00148	CcSEcCtD
Haloperidol—Hepatic function abnormal—Doxorubicin—uterine cancer	0.000245	0.00148	CcSEcCtD
Haloperidol—Photosensitivity—Doxorubicin—uterine cancer	0.000244	0.00147	CcSEcCtD
Haloperidol—Decreased appetite—Dactinomycin—uterine cancer	0.000244	0.00147	CcSEcCtD
Haloperidol—Muscle spasms—Etoposide—uterine cancer	0.000239	0.00144	CcSEcCtD
Haloperidol—ABCB1—mammalian vulva—uterine cancer	0.000239	0.00281	CbGeAlD
Haloperidol—Dizziness—Medroxyprogesterone Acetate—uterine cancer	0.000238	0.00143	CcSEcCtD
Haloperidol—Hypoglycaemia—Epirubicin—uterine cancer	0.000237	0.00143	CcSEcCtD
Haloperidol—Lethargy—Epirubicin—uterine cancer	0.000237	0.00143	CcSEcCtD
Haloperidol—Nausea—Progesterone—uterine cancer	0.000236	0.00142	CcSEcCtD
Haloperidol—Hyponatraemia—Epirubicin—uterine cancer	0.000233	0.0014	CcSEcCtD
Haloperidol—Feeling abnormal—Dactinomycin—uterine cancer	0.000231	0.00139	CcSEcCtD
Haloperidol—CYP1A1—lymph node—uterine cancer	0.00023	0.00271	CbGeAlD
Haloperidol—Anaemia—Etoposide—uterine cancer	0.00023	0.00139	CcSEcCtD
Haloperidol—Vomiting—Medroxyprogesterone Acetate—uterine cancer	0.000229	0.00138	CcSEcCtD
Haloperidol—ABCB1—uterus—uterine cancer	0.000227	0.00268	CbGeAlD
Haloperidol—Dermatitis exfoliative—Doxorubicin—uterine cancer	0.000227	0.00137	CcSEcCtD
Haloperidol—Rash—Medroxyprogesterone Acetate—uterine cancer	0.000227	0.00137	CcSEcCtD
Haloperidol—Dermatitis—Medroxyprogesterone Acetate—uterine cancer	0.000227	0.00137	CcSEcCtD
Haloperidol—Headache—Medroxyprogesterone Acetate—uterine cancer	0.000226	0.00136	CcSEcCtD
Haloperidol—Face oedema—Epirubicin—uterine cancer	0.000224	0.00135	CcSEcCtD
Haloperidol—Vertigo—Etoposide—uterine cancer	0.000224	0.00135	CcSEcCtD
Haloperidol—Leukopenia—Etoposide—uterine cancer	0.000223	0.00134	CcSEcCtD
Haloperidol—Body temperature increased—Dactinomycin—uterine cancer	0.000222	0.00134	CcSEcCtD
Haloperidol—Cardiac arrest—Epirubicin—uterine cancer	0.00022	0.00133	CcSEcCtD
Haloperidol—Hypoglycaemia—Doxorubicin—uterine cancer	0.00022	0.00132	CcSEcCtD
Haloperidol—Lethargy—Doxorubicin—uterine cancer	0.000219	0.00132	CcSEcCtD
Haloperidol—HRH1—lymph node—uterine cancer	0.000218	0.00257	CbGeAlD
Haloperidol—Convulsion—Etoposide—uterine cancer	0.000216	0.0013	CcSEcCtD
Haloperidol—Hyponatraemia—Doxorubicin—uterine cancer	0.000215	0.0013	CcSEcCtD
Haloperidol—Hypertension—Etoposide—uterine cancer	0.000215	0.0013	CcSEcCtD
Haloperidol—Liver function test abnormal—Epirubicin—uterine cancer	0.000214	0.00129	CcSEcCtD
Haloperidol—Nausea—Medroxyprogesterone Acetate—uterine cancer	0.000214	0.00129	CcSEcCtD
Haloperidol—Orthostatic hypotension—Epirubicin—uterine cancer	0.000212	0.00128	CcSEcCtD
Haloperidol—Unspecified disorder of skin and subcutaneous tissue—Etoposide—uterine cancer	0.000211	0.00127	CcSEcCtD
Haloperidol—Breast disorder—Epirubicin—uterine cancer	0.000209	0.00126	CcSEcCtD
Haloperidol—Face oedema—Doxorubicin—uterine cancer	0.000207	0.00125	CcSEcCtD
Haloperidol—Hypersensitivity—Dactinomycin—uterine cancer	0.000207	0.00125	CcSEcCtD
Haloperidol—Confusional state—Etoposide—uterine cancer	0.000205	0.00123	CcSEcCtD
Haloperidol—ABCB1—female reproductive system—uterine cancer	0.000204	0.0024	CbGeAlD
Haloperidol—Cardiac arrest—Doxorubicin—uterine cancer	0.000204	0.00123	CcSEcCtD
Haloperidol—Anaphylactic shock—Etoposide—uterine cancer	0.000203	0.00122	CcSEcCtD
Haloperidol—Dysphagia—Epirubicin—uterine cancer	0.0002	0.00121	CcSEcCtD
Haloperidol—Thrombocytopenia—Etoposide—uterine cancer	0.000199	0.0012	CcSEcCtD
Haloperidol—Tachycardia—Etoposide—uterine cancer	0.000198	0.0012	CcSEcCtD
Haloperidol—Liver function test abnormal—Doxorubicin—uterine cancer	0.000198	0.00119	CcSEcCtD
Haloperidol—Skin disorder—Etoposide—uterine cancer	0.000197	0.00119	CcSEcCtD
Haloperidol—Hyperhidrosis—Etoposide—uterine cancer	0.000196	0.00118	CcSEcCtD
Haloperidol—Orthostatic hypotension—Doxorubicin—uterine cancer	0.000196	0.00118	CcSEcCtD
Haloperidol—Breast disorder—Doxorubicin—uterine cancer	0.000194	0.00117	CcSEcCtD
Haloperidol—Anorexia—Etoposide—uterine cancer	0.000194	0.00117	CcSEcCtD
Haloperidol—Diarrhoea—Dactinomycin—uterine cancer	0.000192	0.00116	CcSEcCtD
Haloperidol—Pancytopenia—Epirubicin—uterine cancer	0.00019	0.00115	CcSEcCtD
Haloperidol—Hypotension—Etoposide—uterine cancer	0.00019	0.00114	CcSEcCtD
Haloperidol—Neutropenia—Epirubicin—uterine cancer	0.000187	0.00113	CcSEcCtD
Haloperidol—ABCB1—female gonad—uterine cancer	0.000186	0.00219	CbGeAlD
Haloperidol—Dysphagia—Doxorubicin—uterine cancer	0.000185	0.00112	CcSEcCtD
Haloperidol—ABCB1—vagina—uterine cancer	0.000185	0.00217	CbGeAlD
Haloperidol—Photosensitivity reaction—Epirubicin—uterine cancer	0.000183	0.0011	CcSEcCtD
Haloperidol—Weight increased—Epirubicin—uterine cancer	0.000182	0.0011	CcSEcCtD
Haloperidol—Weight decreased—Epirubicin—uterine cancer	0.000181	0.00109	CcSEcCtD
Haloperidol—Dyspnoea—Etoposide—uterine cancer	0.000181	0.00109	CcSEcCtD
Haloperidol—Hyperglycaemia—Epirubicin—uterine cancer	0.000181	0.00109	CcSEcCtD
Haloperidol—Somnolence—Etoposide—uterine cancer	0.000181	0.00109	CcSEcCtD
Haloperidol—Drowsiness—Epirubicin—uterine cancer	0.000179	0.00108	CcSEcCtD
Haloperidol—Vomiting—Dactinomycin—uterine cancer	0.000179	0.00108	CcSEcCtD
Haloperidol—Rash—Dactinomycin—uterine cancer	0.000177	0.00107	CcSEcCtD
Haloperidol—Decreased appetite—Etoposide—uterine cancer	0.000177	0.00106	CcSEcCtD
Haloperidol—Pancytopenia—Doxorubicin—uterine cancer	0.000176	0.00106	CcSEcCtD
Haloperidol—Gastrointestinal disorder—Etoposide—uterine cancer	0.000175	0.00106	CcSEcCtD
Haloperidol—Jaundice—Epirubicin—uterine cancer	0.000174	0.00105	CcSEcCtD
Haloperidol—Constipation—Etoposide—uterine cancer	0.000174	0.00105	CcSEcCtD
Haloperidol—Neutropenia—Doxorubicin—uterine cancer	0.000173	0.00104	CcSEcCtD
Haloperidol—Photosensitivity reaction—Doxorubicin—uterine cancer	0.000169	0.00102	CcSEcCtD
Haloperidol—Hepatobiliary disease—Epirubicin—uterine cancer	0.000169	0.00102	CcSEcCtD
Haloperidol—Weight increased—Doxorubicin—uterine cancer	0.000169	0.00102	CcSEcCtD
Haloperidol—Weight decreased—Doxorubicin—uterine cancer	0.000168	0.00101	CcSEcCtD
Haloperidol—Feeling abnormal—Etoposide—uterine cancer	0.000167	0.00101	CcSEcCtD
Haloperidol—Hyperglycaemia—Doxorubicin—uterine cancer	0.000167	0.00101	CcSEcCtD
Haloperidol—Nausea—Dactinomycin—uterine cancer	0.000167	0.00101	CcSEcCtD
Haloperidol—Agranulocytosis—Epirubicin—uterine cancer	0.000167	0.001	CcSEcCtD
Haloperidol—Drowsiness—Doxorubicin—uterine cancer	0.000165	0.000996	CcSEcCtD
Haloperidol—Urticaria—Etoposide—uterine cancer	0.000161	0.000973	CcSEcCtD
Haloperidol—Jaundice—Doxorubicin—uterine cancer	0.000161	0.000971	CcSEcCtD
Haloperidol—Body temperature increased—Etoposide—uterine cancer	0.000161	0.000968	CcSEcCtD
Haloperidol—Hepatitis—Epirubicin—uterine cancer	0.00016	0.000966	CcSEcCtD
Haloperidol—Urinary tract disorder—Epirubicin—uterine cancer	0.000158	0.000954	CcSEcCtD
Haloperidol—Connective tissue disorder—Epirubicin—uterine cancer	0.000158	0.00095	CcSEcCtD
Haloperidol—Urethral disorder—Epirubicin—uterine cancer	0.000157	0.000947	CcSEcCtD
Haloperidol—Hepatobiliary disease—Doxorubicin—uterine cancer	0.000156	0.000942	CcSEcCtD
Haloperidol—Visual impairment—Epirubicin—uterine cancer	0.000155	0.000931	CcSEcCtD
Haloperidol—Agranulocytosis—Doxorubicin—uterine cancer	0.000154	0.00093	CcSEcCtD
Haloperidol—Eye disorder—Epirubicin—uterine cancer	0.00015	0.000903	CcSEcCtD
Haloperidol—Hypersensitivity—Etoposide—uterine cancer	0.00015	0.000902	CcSEcCtD
Haloperidol—Cardiac disorder—Epirubicin—uterine cancer	0.000149	0.000897	CcSEcCtD
Haloperidol—Hepatitis—Doxorubicin—uterine cancer	0.000148	0.000894	CcSEcCtD
Haloperidol—Urinary tract disorder—Doxorubicin—uterine cancer	0.000147	0.000883	CcSEcCtD
Haloperidol—Connective tissue disorder—Doxorubicin—uterine cancer	0.000146	0.000879	CcSEcCtD
Haloperidol—Angiopathy—Epirubicin—uterine cancer	0.000145	0.000877	CcSEcCtD
Haloperidol—Urethral disorder—Doxorubicin—uterine cancer	0.000145	0.000876	CcSEcCtD
Haloperidol—Immune system disorder—Epirubicin—uterine cancer	0.000145	0.000873	CcSEcCtD
Haloperidol—Mediastinal disorder—Epirubicin—uterine cancer	0.000145	0.000871	CcSEcCtD
Haloperidol—Pruritus—Etoposide—uterine cancer	0.000144	0.000867	CcSEcCtD
Haloperidol—Visual impairment—Doxorubicin—uterine cancer	0.000143	0.000862	CcSEcCtD
Haloperidol—Alopecia—Epirubicin—uterine cancer	0.000142	0.000854	CcSEcCtD
Haloperidol—Mental disorder—Epirubicin—uterine cancer	0.00014	0.000847	CcSEcCtD
Haloperidol—Malnutrition—Epirubicin—uterine cancer	0.00014	0.000841	CcSEcCtD
Haloperidol—Diarrhoea—Etoposide—uterine cancer	0.000139	0.000838	CcSEcCtD
Haloperidol—Eye disorder—Doxorubicin—uterine cancer	0.000139	0.000836	CcSEcCtD
Haloperidol—Cardiac disorder—Doxorubicin—uterine cancer	0.000138	0.00083	CcSEcCtD
Haloperidol—Angiopathy—Doxorubicin—uterine cancer	0.000135	0.000811	CcSEcCtD
Haloperidol—Dizziness—Etoposide—uterine cancer	0.000134	0.00081	CcSEcCtD
Haloperidol—Muscle spasms—Epirubicin—uterine cancer	0.000134	0.000809	CcSEcCtD
Haloperidol—Immune system disorder—Doxorubicin—uterine cancer	0.000134	0.000808	CcSEcCtD
Haloperidol—Mediastinal disorder—Doxorubicin—uterine cancer	0.000134	0.000806	CcSEcCtD
Haloperidol—Vision blurred—Epirubicin—uterine cancer	0.000132	0.000793	CcSEcCtD
Haloperidol—Alopecia—Doxorubicin—uterine cancer	0.000131	0.00079	CcSEcCtD
Haloperidol—Mental disorder—Doxorubicin—uterine cancer	0.00013	0.000783	CcSEcCtD
Haloperidol—Vomiting—Etoposide—uterine cancer	0.000129	0.000779	CcSEcCtD
Haloperidol—Malnutrition—Doxorubicin—uterine cancer	0.000129	0.000778	CcSEcCtD
Haloperidol—Anaemia—Epirubicin—uterine cancer	0.000129	0.000778	CcSEcCtD
Haloperidol—Agitation—Epirubicin—uterine cancer	0.000128	0.000773	CcSEcCtD
Haloperidol—Rash—Etoposide—uterine cancer	0.000128	0.000772	CcSEcCtD
Haloperidol—Dermatitis—Etoposide—uterine cancer	0.000128	0.000772	CcSEcCtD
Haloperidol—Headache—Etoposide—uterine cancer	0.000127	0.000767	CcSEcCtD
Haloperidol—Vertigo—Epirubicin—uterine cancer	0.000125	0.000756	CcSEcCtD
Haloperidol—Leukopenia—Epirubicin—uterine cancer	0.000125	0.000753	CcSEcCtD
Haloperidol—Muscle spasms—Doxorubicin—uterine cancer	0.000124	0.000748	CcSEcCtD
Haloperidol—Vision blurred—Doxorubicin—uterine cancer	0.000122	0.000734	CcSEcCtD
Haloperidol—Convulsion—Epirubicin—uterine cancer	0.000121	0.000729	CcSEcCtD
Haloperidol—Nausea—Etoposide—uterine cancer	0.000121	0.000728	CcSEcCtD
Haloperidol—Hypertension—Epirubicin—uterine cancer	0.000121	0.000726	CcSEcCtD
Haloperidol—ABCB1—lymph node—uterine cancer	0.00012	0.00141	CbGeAlD
Haloperidol—Anaemia—Doxorubicin—uterine cancer	0.000119	0.000719	CcSEcCtD
Haloperidol—Agitation—Doxorubicin—uterine cancer	0.000119	0.000715	CcSEcCtD
Haloperidol—Anxiety—Epirubicin—uterine cancer	0.000118	0.000714	CcSEcCtD
Haloperidol—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—uterine cancer	0.000118	0.000711	CcSEcCtD
Haloperidol—Dry mouth—Epirubicin—uterine cancer	0.000116	0.0007	CcSEcCtD
Haloperidol—Vertigo—Doxorubicin—uterine cancer	0.000116	0.000699	CcSEcCtD
Haloperidol—Leukopenia—Doxorubicin—uterine cancer	0.000116	0.000697	CcSEcCtD
Haloperidol—Confusional state—Epirubicin—uterine cancer	0.000115	0.000692	CcSEcCtD
Haloperidol—Anaphylactic shock—Epirubicin—uterine cancer	0.000114	0.000687	CcSEcCtD
Haloperidol—Oedema—Epirubicin—uterine cancer	0.000114	0.000687	CcSEcCtD
Haloperidol—Convulsion—Doxorubicin—uterine cancer	0.000112	0.000674	CcSEcCtD
Haloperidol—Nervous system disorder—Epirubicin—uterine cancer	0.000112	0.000673	CcSEcCtD
Haloperidol—Thrombocytopenia—Epirubicin—uterine cancer	0.000112	0.000672	CcSEcCtD
Haloperidol—Hypertension—Doxorubicin—uterine cancer	0.000112	0.000672	CcSEcCtD
Haloperidol—Tachycardia—Epirubicin—uterine cancer	0.000111	0.00067	CcSEcCtD
Haloperidol—Skin disorder—Epirubicin—uterine cancer	0.000111	0.000667	CcSEcCtD
Haloperidol—Hyperhidrosis—Epirubicin—uterine cancer	0.00011	0.000664	CcSEcCtD
Haloperidol—Anxiety—Doxorubicin—uterine cancer	0.00011	0.00066	CcSEcCtD
Haloperidol—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—uterine cancer	0.000109	0.000658	CcSEcCtD
Haloperidol—Anorexia—Epirubicin—uterine cancer	0.000109	0.000654	CcSEcCtD
Haloperidol—Dry mouth—Doxorubicin—uterine cancer	0.000108	0.000648	CcSEcCtD
Haloperidol—Hypotension—Epirubicin—uterine cancer	0.000106	0.000642	CcSEcCtD
Haloperidol—Confusional state—Doxorubicin—uterine cancer	0.000106	0.000641	CcSEcCtD
Haloperidol—Anaphylactic shock—Doxorubicin—uterine cancer	0.000105	0.000635	CcSEcCtD
Haloperidol—Oedema—Doxorubicin—uterine cancer	0.000105	0.000635	CcSEcCtD
Haloperidol—Nervous system disorder—Doxorubicin—uterine cancer	0.000103	0.000623	CcSEcCtD
Haloperidol—Thrombocytopenia—Doxorubicin—uterine cancer	0.000103	0.000622	CcSEcCtD
Haloperidol—Insomnia—Epirubicin—uterine cancer	0.000103	0.000621	CcSEcCtD
Haloperidol—Tachycardia—Doxorubicin—uterine cancer	0.000103	0.00062	CcSEcCtD
Haloperidol—Skin disorder—Doxorubicin—uterine cancer	0.000102	0.000617	CcSEcCtD
Haloperidol—Hyperhidrosis—Doxorubicin—uterine cancer	0.000102	0.000614	CcSEcCtD
Haloperidol—Dyspnoea—Epirubicin—uterine cancer	0.000102	0.000612	CcSEcCtD
Haloperidol—Somnolence—Epirubicin—uterine cancer	0.000101	0.00061	CcSEcCtD
Haloperidol—Anorexia—Doxorubicin—uterine cancer	0.0001	0.000606	CcSEcCtD
Haloperidol—Dyspepsia—Epirubicin—uterine cancer	0.0001	0.000604	CcSEcCtD
Haloperidol—Decreased appetite—Epirubicin—uterine cancer	9.9e-05	0.000597	CcSEcCtD
Haloperidol—Hypotension—Doxorubicin—uterine cancer	9.85e-05	0.000594	CcSEcCtD
Haloperidol—Gastrointestinal disorder—Epirubicin—uterine cancer	9.83e-05	0.000593	CcSEcCtD
Haloperidol—Constipation—Epirubicin—uterine cancer	9.74e-05	0.000587	CcSEcCtD
Haloperidol—Insomnia—Doxorubicin—uterine cancer	9.53e-05	0.000575	CcSEcCtD
Haloperidol—Dyspnoea—Doxorubicin—uterine cancer	9.4e-05	0.000566	CcSEcCtD
Haloperidol—Feeling abnormal—Epirubicin—uterine cancer	9.39e-05	0.000566	CcSEcCtD
Haloperidol—Somnolence—Doxorubicin—uterine cancer	9.37e-05	0.000565	CcSEcCtD
Haloperidol—Dyspepsia—Doxorubicin—uterine cancer	9.28e-05	0.000559	CcSEcCtD
Haloperidol—Decreased appetite—Doxorubicin—uterine cancer	9.16e-05	0.000552	CcSEcCtD
Haloperidol—Gastrointestinal disorder—Doxorubicin—uterine cancer	9.1e-05	0.000548	CcSEcCtD
Haloperidol—Urticaria—Epirubicin—uterine cancer	9.05e-05	0.000545	CcSEcCtD
Haloperidol—Constipation—Doxorubicin—uterine cancer	9.01e-05	0.000543	CcSEcCtD
Haloperidol—Body temperature increased—Epirubicin—uterine cancer	9.01e-05	0.000543	CcSEcCtD
Haloperidol—Feeling abnormal—Doxorubicin—uterine cancer	8.69e-05	0.000523	CcSEcCtD
Haloperidol—Hypersensitivity—Epirubicin—uterine cancer	8.39e-05	0.000506	CcSEcCtD
Haloperidol—Urticaria—Doxorubicin—uterine cancer	8.37e-05	0.000505	CcSEcCtD
Haloperidol—Body temperature increased—Doxorubicin—uterine cancer	8.33e-05	0.000502	CcSEcCtD
Haloperidol—Pruritus—Epirubicin—uterine cancer	8.06e-05	0.000486	CcSEcCtD
Haloperidol—Diarrhoea—Epirubicin—uterine cancer	7.79e-05	0.00047	CcSEcCtD
Haloperidol—Hypersensitivity—Doxorubicin—uterine cancer	7.77e-05	0.000468	CcSEcCtD
Haloperidol—Dizziness—Epirubicin—uterine cancer	7.53e-05	0.000454	CcSEcCtD
Haloperidol—Pruritus—Doxorubicin—uterine cancer	7.46e-05	0.000449	CcSEcCtD
Haloperidol—Vomiting—Epirubicin—uterine cancer	7.24e-05	0.000437	CcSEcCtD
Haloperidol—Diarrhoea—Doxorubicin—uterine cancer	7.21e-05	0.000435	CcSEcCtD
Haloperidol—Rash—Epirubicin—uterine cancer	7.18e-05	0.000433	CcSEcCtD
Haloperidol—Dermatitis—Epirubicin—uterine cancer	7.18e-05	0.000432	CcSEcCtD
Haloperidol—Headache—Epirubicin—uterine cancer	7.14e-05	0.00043	CcSEcCtD
Haloperidol—Dizziness—Doxorubicin—uterine cancer	6.97e-05	0.00042	CcSEcCtD
Haloperidol—Nausea—Epirubicin—uterine cancer	6.77e-05	0.000408	CcSEcCtD
Haloperidol—Vomiting—Doxorubicin—uterine cancer	6.7e-05	0.000404	CcSEcCtD
Haloperidol—Rash—Doxorubicin—uterine cancer	6.65e-05	0.000401	CcSEcCtD
Haloperidol—Dermatitis—Doxorubicin—uterine cancer	6.64e-05	0.0004	CcSEcCtD
Haloperidol—Headache—Doxorubicin—uterine cancer	6.6e-05	0.000398	CcSEcCtD
Haloperidol—Nausea—Doxorubicin—uterine cancer	6.26e-05	0.000377	CcSEcCtD
Haloperidol—HRH1—Signaling Pathways—FGFR2—uterine cancer	7.8e-06	0.00013	CbGpPWpGaD
Haloperidol—HTR2B—Signaling by GPCR—KRAS—uterine cancer	7.77e-06	0.00013	CbGpPWpGaD
Haloperidol—HTR1D—Signaling by GPCR—PIK3CA—uterine cancer	7.76e-06	0.00013	CbGpPWpGaD
Haloperidol—CYP3A4—Metabolism—AKR1C1—uterine cancer	7.74e-06	0.000129	CbGpPWpGaD
Haloperidol—CYP1A2—Metabolism—AKR1C3—uterine cancer	7.72e-06	0.000129	CbGpPWpGaD
Haloperidol—CYP2C19—Metabolism—CYP19A1—uterine cancer	7.72e-06	0.000129	CbGpPWpGaD
Haloperidol—CYP2C19—Metabolism—STK11—uterine cancer	7.72e-06	0.000129	CbGpPWpGaD
Haloperidol—HTR1D—Signaling Pathways—ERBB2—uterine cancer	7.62e-06	0.000127	CbGpPWpGaD
Haloperidol—HTR1B—Signaling by GPCR—PIK3CA—uterine cancer	7.6e-06	0.000127	CbGpPWpGaD
Haloperidol—ABCB1—Metabolism—STK11—uterine cancer	7.54e-06	0.000126	CbGpPWpGaD
Haloperidol—ABCB1—Metabolism—CYP19A1—uterine cancer	7.54e-06	0.000126	CbGpPWpGaD
Haloperidol—CYP3A5—Metabolism—MTHFR—uterine cancer	7.5e-06	0.000125	CbGpPWpGaD
Haloperidol—DRD4—Signaling by GPCR—PIK3CA—uterine cancer	7.48e-06	0.000125	CbGpPWpGaD
Haloperidol—HTR1B—Signaling Pathways—ERBB2—uterine cancer	7.46e-06	0.000125	CbGpPWpGaD
Haloperidol—DRD1—GPCR downstream signaling—PIK3CA—uterine cancer	7.41e-06	0.000124	CbGpPWpGaD
Haloperidol—DRD4—Signaling Pathways—ERBB2—uterine cancer	7.34e-06	0.000123	CbGpPWpGaD
Haloperidol—DRD1—Signaling by GPCR—KRAS—uterine cancer	7.33e-06	0.000122	CbGpPWpGaD
Haloperidol—DRD3—GPCR downstream signaling—PIK3CA—uterine cancer	7.31e-06	0.000122	CbGpPWpGaD
Haloperidol—CYP2C19—Metabolism of lipids and lipoproteins—PTEN—uterine cancer	7.25e-06	0.000121	CbGpPWpGaD
Haloperidol—DRD3—Signaling by GPCR—KRAS—uterine cancer	7.23e-06	0.000121	CbGpPWpGaD
Haloperidol—HTR1D—Signaling Pathways—CXCL8—uterine cancer	7.23e-06	0.000121	CbGpPWpGaD
Haloperidol—HTR1D—Signaling by GPCR—HRAS—uterine cancer	7.18e-06	0.00012	CbGpPWpGaD
Haloperidol—HTR2B—Signaling by GPCR—PIK3CA—uterine cancer	7.14e-06	0.000119	CbGpPWpGaD
Haloperidol—CYP2D6—Metabolism—STK11—uterine cancer	7.1e-06	0.000119	CbGpPWpGaD
Haloperidol—CYP2D6—Metabolism—CYP19A1—uterine cancer	7.1e-06	0.000119	CbGpPWpGaD
Haloperidol—CYP1A1—Metabolism—MTHFR—uterine cancer	7.09e-06	0.000118	CbGpPWpGaD
Haloperidol—HTR1B—Signaling Pathways—CXCL8—uterine cancer	7.08e-06	0.000118	CbGpPWpGaD
Haloperidol—HTR1D—Signaling Pathways—CDKN1B—uterine cancer	7.06e-06	0.000118	CbGpPWpGaD
Haloperidol—CYP2C9—Metabolism—STK11—uterine cancer	7.04e-06	0.000118	CbGpPWpGaD
Haloperidol—CYP2C9—Metabolism—CYP19A1—uterine cancer	7.04e-06	0.000118	CbGpPWpGaD
Haloperidol—HTR1B—Signaling by GPCR—HRAS—uterine cancer	7.03e-06	0.000117	CbGpPWpGaD
Haloperidol—HTR2B—Signaling Pathways—ERBB2—uterine cancer	7.01e-06	0.000117	CbGpPWpGaD
Haloperidol—HTR1D—GPCR downstream signaling—AKT1—uterine cancer	6.98e-06	0.000117	CbGpPWpGaD
Haloperidol—DRD4—Signaling Pathways—CXCL8—uterine cancer	6.96e-06	0.000116	CbGpPWpGaD
Haloperidol—DRD4—Signaling by GPCR—HRAS—uterine cancer	6.92e-06	0.000115	CbGpPWpGaD
Haloperidol—CYP2C19—Metabolism of lipids and lipoproteins—EP300—uterine cancer	6.91e-06	0.000115	CbGpPWpGaD
Haloperidol—HTR1B—Signaling Pathways—CDKN1B—uterine cancer	6.91e-06	0.000115	CbGpPWpGaD
Haloperidol—CYP3A4—Metabolism—RRM2—uterine cancer	6.9e-06	0.000115	CbGpPWpGaD
Haloperidol—UGT1A9—Metabolism—PTEN—uterine cancer	6.87e-06	0.000115	CbGpPWpGaD
Haloperidol—HTR1B—GPCR downstream signaling—AKT1—uterine cancer	6.84e-06	0.000114	CbGpPWpGaD
Haloperidol—DRD4—Signaling Pathways—CDKN1B—uterine cancer	6.8e-06	0.000114	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—ESR1—uterine cancer	6.8e-06	0.000114	CbGpPWpGaD
Haloperidol—DRD1—Signaling by GPCR—PIK3CA—uterine cancer	6.73e-06	0.000112	CbGpPWpGaD
Haloperidol—DRD4—GPCR downstream signaling—AKT1—uterine cancer	6.73e-06	0.000112	CbGpPWpGaD
Haloperidol—CYP3A4—Metabolism—DCN—uterine cancer	6.7e-06	0.000112	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—ESR1—uterine cancer	6.69e-06	0.000112	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—ESR1—uterine cancer	6.68e-06	0.000111	CbGpPWpGaD
Haloperidol—HTR1D—Signaling Pathways—CTNNB1—uterine cancer	6.67e-06	0.000111	CbGpPWpGaD
Haloperidol—HTR2B—Signaling Pathways—CXCL8—uterine cancer	6.65e-06	0.000111	CbGpPWpGaD
Haloperidol—DRD3—Signaling by GPCR—PIK3CA—uterine cancer	6.64e-06	0.000111	CbGpPWpGaD
Haloperidol—DRD1—Signaling Pathways—ERBB2—uterine cancer	6.61e-06	0.00011	CbGpPWpGaD
Haloperidol—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—uterine cancer	6.61e-06	0.00011	CbGpPWpGaD
Haloperidol—HTR2B—Signaling by GPCR—HRAS—uterine cancer	6.6e-06	0.00011	CbGpPWpGaD
Haloperidol—UGT1A9—Metabolism—EP300—uterine cancer	6.55e-06	0.000109	CbGpPWpGaD
Haloperidol—HTR1B—Signaling Pathways—CTNNB1—uterine cancer	6.53e-06	0.000109	CbGpPWpGaD
Haloperidol—DRD3—Signaling Pathways—ERBB2—uterine cancer	6.52e-06	0.000109	CbGpPWpGaD
Haloperidol—HTR1D—Signaling Pathways—PTEN—uterine cancer	6.5e-06	0.000108	CbGpPWpGaD
Haloperidol—HTR2B—Signaling Pathways—CDKN1B—uterine cancer	6.49e-06	0.000108	CbGpPWpGaD
Haloperidol—DRD2—Signaling by GPCR—NRAS—uterine cancer	6.43e-06	0.000107	CbGpPWpGaD
Haloperidol—DRD4—Signaling Pathways—CTNNB1—uterine cancer	6.42e-06	0.000107	CbGpPWpGaD
Haloperidol—HTR2B—GPCR downstream signaling—AKT1—uterine cancer	6.42e-06	0.000107	CbGpPWpGaD
Haloperidol—HTR1B—Signaling Pathways—PTEN—uterine cancer	6.36e-06	0.000106	CbGpPWpGaD
Haloperidol—HTR1D—Signaling by GPCR—AKT1—uterine cancer	6.34e-06	0.000106	CbGpPWpGaD
Haloperidol—HTR2A—Signaling by GPCR—NRAS—uterine cancer	6.32e-06	0.000106	CbGpPWpGaD
Haloperidol—CYP3A4—Metabolism—CYP11A1—uterine cancer	6.31e-06	0.000105	CbGpPWpGaD
Haloperidol—HRH1—Signaling by GPCR—NRAS—uterine cancer	6.31e-06	0.000105	CbGpPWpGaD
Haloperidol—CYP2C9—Metabolism of lipids and lipoproteins—EP300—uterine cancer	6.3e-06	0.000105	CbGpPWpGaD
Haloperidol—DRD1—Signaling Pathways—CXCL8—uterine cancer	6.27e-06	0.000105	CbGpPWpGaD
Haloperidol—DRD4—Signaling Pathways—PTEN—uterine cancer	6.26e-06	0.000105	CbGpPWpGaD
Haloperidol—CYP1A1—Metabolism of lipids and lipoproteins—PIK3CA—uterine cancer	6.25e-06	0.000104	CbGpPWpGaD
Haloperidol—DRD1—Signaling by GPCR—HRAS—uterine cancer	6.23e-06	0.000104	CbGpPWpGaD
Haloperidol—HTR1B—Signaling by GPCR—AKT1—uterine cancer	6.21e-06	0.000104	CbGpPWpGaD
Haloperidol—HTR1D—Signaling Pathways—EP300—uterine cancer	6.2e-06	0.000103	CbGpPWpGaD
Haloperidol—DRD3—Signaling Pathways—CXCL8—uterine cancer	6.18e-06	0.000103	CbGpPWpGaD
Haloperidol—DRD3—Signaling by GPCR—HRAS—uterine cancer	6.14e-06	0.000103	CbGpPWpGaD
Haloperidol—HTR2B—Signaling Pathways—CTNNB1—uterine cancer	6.13e-06	0.000102	CbGpPWpGaD
Haloperidol—DRD1—Signaling Pathways—CDKN1B—uterine cancer	6.12e-06	0.000102	CbGpPWpGaD
Haloperidol—DRD4—Signaling by GPCR—AKT1—uterine cancer	6.11e-06	0.000102	CbGpPWpGaD
Haloperidol—HTR1B—Signaling Pathways—EP300—uterine cancer	6.07e-06	0.000101	CbGpPWpGaD
Haloperidol—DRD1—GPCR downstream signaling—AKT1—uterine cancer	6.06e-06	0.000101	CbGpPWpGaD
Haloperidol—DRD3—Signaling Pathways—CDKN1B—uterine cancer	6.04e-06	0.000101	CbGpPWpGaD
Haloperidol—CYP1A2—Metabolism—STK11—uterine cancer	6.02e-06	0.0001	CbGpPWpGaD
Haloperidol—CYP1A2—Metabolism—CYP19A1—uterine cancer	6.02e-06	0.0001	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—CCL2—uterine cancer	5.99e-06	9.99e-05	CbGpPWpGaD
Haloperidol—HTR2B—Signaling Pathways—PTEN—uterine cancer	5.98e-06	9.98e-05	CbGpPWpGaD
Haloperidol—DRD3—GPCR downstream signaling—AKT1—uterine cancer	5.97e-06	9.97e-05	CbGpPWpGaD
Haloperidol—DRD4—Signaling Pathways—EP300—uterine cancer	5.97e-06	9.97e-05	CbGpPWpGaD
Haloperidol—CYP3A4—Metabolism—AKR1C3—uterine cancer	5.96e-06	9.95e-05	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—CCL2—uterine cancer	5.89e-06	9.83e-05	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—CCL2—uterine cancer	5.88e-06	9.81e-05	CbGpPWpGaD
Haloperidol—HTR1D—Signaling Pathways—VEGFA—uterine cancer	5.87e-06	9.8e-05	CbGpPWpGaD
Haloperidol—HTR2B—Signaling by GPCR—AKT1—uterine cancer	5.83e-06	9.73e-05	CbGpPWpGaD
Haloperidol—CYP2C19—Metabolism—MTHFR—uterine cancer	5.8e-06	9.69e-05	CbGpPWpGaD
Haloperidol—HTR1D—Signaling Pathways—NRAS—uterine cancer	5.8e-06	9.68e-05	CbGpPWpGaD
Haloperidol—DRD1—Signaling Pathways—CTNNB1—uterine cancer	5.78e-06	9.65e-05	CbGpPWpGaD
Haloperidol—CYP3A7—Metabolism—PTEN—uterine cancer	5.78e-06	9.64e-05	CbGpPWpGaD
Haloperidol—HTR1B—Signaling Pathways—VEGFA—uterine cancer	5.75e-06	9.59e-05	CbGpPWpGaD
Haloperidol—DRD3—Signaling Pathways—CTNNB1—uterine cancer	5.71e-06	9.53e-05	CbGpPWpGaD
Haloperidol—HTR2B—Signaling Pathways—EP300—uterine cancer	5.7e-06	9.52e-05	CbGpPWpGaD
Haloperidol—HTR1B—Signaling Pathways—NRAS—uterine cancer	5.68e-06	9.48e-05	CbGpPWpGaD
Haloperidol—ABCB1—Metabolism—MTHFR—uterine cancer	5.66e-06	9.45e-05	CbGpPWpGaD
Haloperidol—DRD4—Signaling Pathways—VEGFA—uterine cancer	5.66e-06	9.44e-05	CbGpPWpGaD
Haloperidol—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—uterine cancer	5.65e-06	9.43e-05	CbGpPWpGaD
Haloperidol—DRD1—Signaling Pathways—PTEN—uterine cancer	5.64e-06	9.41e-05	CbGpPWpGaD
Haloperidol—DRD2—GPCR downstream signaling—PIK3CA—uterine cancer	5.6e-06	9.34e-05	CbGpPWpGaD
Haloperidol—DRD4—Signaling Pathways—NRAS—uterine cancer	5.59e-06	9.33e-05	CbGpPWpGaD
Haloperidol—DRD3—Signaling Pathways—PTEN—uterine cancer	5.56e-06	9.28e-05	CbGpPWpGaD
Haloperidol—DRD2—Signaling by GPCR—KRAS—uterine cancer	5.53e-06	9.23e-05	CbGpPWpGaD
Haloperidol—CYP3A7—Metabolism—EP300—uterine cancer	5.51e-06	9.19e-05	CbGpPWpGaD
Haloperidol—HTR2A—GPCR downstream signaling—PIK3CA—uterine cancer	5.51e-06	9.19e-05	CbGpPWpGaD
Haloperidol—DRD1—Signaling by GPCR—AKT1—uterine cancer	5.5e-06	9.18e-05	CbGpPWpGaD
Haloperidol—HRH1—GPCR downstream signaling—PIK3CA—uterine cancer	5.49e-06	9.17e-05	CbGpPWpGaD
Haloperidol—HTR2A—Signaling by GPCR—KRAS—uterine cancer	5.44e-06	9.09e-05	CbGpPWpGaD
Haloperidol—HRH1—Signaling by GPCR—KRAS—uterine cancer	5.43e-06	9.07e-05	CbGpPWpGaD
Haloperidol—DRD3—Signaling by GPCR—AKT1—uterine cancer	5.43e-06	9.06e-05	CbGpPWpGaD
Haloperidol—HTR2B—Signaling Pathways—VEGFA—uterine cancer	5.4e-06	9.01e-05	CbGpPWpGaD
Haloperidol—CYP1A2—Metabolism of lipids and lipoproteins—EP300—uterine cancer	5.39e-06	8.99e-05	CbGpPWpGaD
Haloperidol—DRD1—Signaling Pathways—EP300—uterine cancer	5.38e-06	8.97e-05	CbGpPWpGaD
Haloperidol—CYP2D6—Metabolism—MTHFR—uterine cancer	5.34e-06	8.91e-05	CbGpPWpGaD
Haloperidol—HTR2B—Signaling Pathways—NRAS—uterine cancer	5.33e-06	8.9e-05	CbGpPWpGaD
Haloperidol—DRD3—Signaling Pathways—EP300—uterine cancer	5.3e-06	8.85e-05	CbGpPWpGaD
Haloperidol—CYP2C9—Metabolism—MTHFR—uterine cancer	5.29e-06	8.83e-05	CbGpPWpGaD
Haloperidol—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CA—uterine cancer	5.11e-06	8.54e-05	CbGpPWpGaD
Haloperidol—DRD1—Signaling Pathways—VEGFA—uterine cancer	5.09e-06	8.5e-05	CbGpPWpGaD
Haloperidol—DRD2—Signaling by GPCR—PIK3CA—uterine cancer	5.08e-06	8.48e-05	CbGpPWpGaD
Haloperidol—DRD1—Signaling Pathways—NRAS—uterine cancer	5.03e-06	8.39e-05	CbGpPWpGaD
Haloperidol—DRD3—Signaling Pathways—VEGFA—uterine cancer	5.02e-06	8.39e-05	CbGpPWpGaD
Haloperidol—HTR2A—Signaling by GPCR—PIK3CA—uterine cancer	5e-06	8.35e-05	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—ERBB2—uterine cancer	4.99e-06	8.33e-05	CbGpPWpGaD
Haloperidol—HRH1—Signaling by GPCR—PIK3CA—uterine cancer	4.99e-06	8.33e-05	CbGpPWpGaD
Haloperidol—HTR1D—Signaling Pathways—KRAS—uterine cancer	4.99e-06	8.33e-05	CbGpPWpGaD
Haloperidol—DRD3—Signaling Pathways—NRAS—uterine cancer	4.96e-06	8.28e-05	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—ERBB2—uterine cancer	4.91e-06	8.2e-05	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—ERBB2—uterine cancer	4.9e-06	8.18e-05	CbGpPWpGaD
Haloperidol—HTR1B—Signaling Pathways—KRAS—uterine cancer	4.89e-06	8.16e-05	CbGpPWpGaD
Haloperidol—UGT1A9—Metabolism—PIK3CA—uterine cancer	4.84e-06	8.09e-05	CbGpPWpGaD
Haloperidol—DRD4—Signaling Pathways—KRAS—uterine cancer	4.81e-06	8.03e-05	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—CXCL8—uterine cancer	4.73e-06	7.9e-05	CbGpPWpGaD
Haloperidol—DRD2—Signaling by GPCR—HRAS—uterine cancer	4.7e-06	7.85e-05	CbGpPWpGaD
Haloperidol—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—uterine cancer	4.66e-06	7.78e-05	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—CXCL8—uterine cancer	4.66e-06	7.77e-05	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—CXCL8—uterine cancer	4.65e-06	7.76e-05	CbGpPWpGaD
Haloperidol—CYP3A4—Metabolism—STK11—uterine cancer	4.64e-06	7.75e-05	CbGpPWpGaD
Haloperidol—CYP3A4—Metabolism—CYP19A1—uterine cancer	4.64e-06	7.75e-05	CbGpPWpGaD
Haloperidol—HTR2A—Signaling by GPCR—HRAS—uterine cancer	4.63e-06	7.72e-05	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—CDKN1B—uterine cancer	4.62e-06	7.72e-05	CbGpPWpGaD
Haloperidol—HRH1—Signaling by GPCR—HRAS—uterine cancer	4.62e-06	7.71e-05	CbGpPWpGaD
Haloperidol—HTR2B—Signaling Pathways—KRAS—uterine cancer	4.59e-06	7.66e-05	CbGpPWpGaD
Haloperidol—HTR1D—Signaling Pathways—PIK3CA—uterine cancer	4.58e-06	7.65e-05	CbGpPWpGaD
Haloperidol—DRD2—GPCR downstream signaling—AKT1—uterine cancer	4.57e-06	7.63e-05	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—CDKN1B—uterine cancer	4.55e-06	7.59e-05	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—CDKN1B—uterine cancer	4.54e-06	7.58e-05	CbGpPWpGaD
Haloperidol—CYP1A2—Metabolism—MTHFR—uterine cancer	4.52e-06	7.55e-05	CbGpPWpGaD
Haloperidol—HTR2A—GPCR downstream signaling—AKT1—uterine cancer	4.5e-06	7.51e-05	CbGpPWpGaD
Haloperidol—HRH1—GPCR downstream signaling—AKT1—uterine cancer	4.49e-06	7.49e-05	CbGpPWpGaD
Haloperidol—HTR1B—Signaling Pathways—PIK3CA—uterine cancer	4.49e-06	7.49e-05	CbGpPWpGaD
Haloperidol—HTR1D—Signaling Pathways—TP53—uterine cancer	4.43e-06	7.4e-05	CbGpPWpGaD
Haloperidol—DRD4—Signaling Pathways—PIK3CA—uterine cancer	4.42e-06	7.37e-05	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—CTNNB1—uterine cancer	4.37e-06	7.29e-05	CbGpPWpGaD
Haloperidol—HTR1B—Signaling Pathways—TP53—uterine cancer	4.34e-06	7.25e-05	CbGpPWpGaD
Haloperidol—DRD1—Signaling Pathways—KRAS—uterine cancer	4.33e-06	7.23e-05	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—CTNNB1—uterine cancer	4.3e-06	7.17e-05	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—CTNNB1—uterine cancer	4.29e-06	7.16e-05	CbGpPWpGaD
Haloperidol—DRD4—Signaling Pathways—TP53—uterine cancer	4.27e-06	7.13e-05	CbGpPWpGaD
Haloperidol—DRD3—Signaling Pathways—KRAS—uterine cancer	4.27e-06	7.13e-05	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—PTEN—uterine cancer	4.26e-06	7.1e-05	CbGpPWpGaD
Haloperidol—HTR1D—Signaling Pathways—HRAS—uterine cancer	4.24e-06	7.08e-05	CbGpPWpGaD
Haloperidol—HTR2B—Signaling Pathways—PIK3CA—uterine cancer	4.22e-06	7.04e-05	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—PTEN—uterine cancer	4.19e-06	6.99e-05	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—PTEN—uterine cancer	4.18e-06	6.98e-05	CbGpPWpGaD
Haloperidol—CYP3A5—Metabolism—PTEN—uterine cancer	4.17e-06	6.97e-05	CbGpPWpGaD
Haloperidol—HTR1B—Signaling Pathways—HRAS—uterine cancer	4.15e-06	6.93e-05	CbGpPWpGaD
Haloperidol—DRD2—Signaling by GPCR—AKT1—uterine cancer	4.15e-06	6.93e-05	CbGpPWpGaD
Haloperidol—DRD4—Signaling Pathways—HRAS—uterine cancer	4.09e-06	6.82e-05	CbGpPWpGaD
Haloperidol—HTR2A—Signaling by GPCR—AKT1—uterine cancer	4.09e-06	6.82e-05	CbGpPWpGaD
Haloperidol—HTR2B—Signaling Pathways—TP53—uterine cancer	4.08e-06	6.81e-05	CbGpPWpGaD
Haloperidol—HRH1—Signaling by GPCR—AKT1—uterine cancer	4.08e-06	6.8e-05	CbGpPWpGaD
Haloperidol—CYP3A7—Metabolism—PIK3CA—uterine cancer	4.07e-06	6.8e-05	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—EP300—uterine cancer	4.06e-06	6.78e-05	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—EP300—uterine cancer	3.99e-06	6.67e-05	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—EP300—uterine cancer	3.98e-06	6.65e-05	CbGpPWpGaD
Haloperidol—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—uterine cancer	3.98e-06	6.65e-05	CbGpPWpGaD
Haloperidol—CYP3A5—Metabolism—EP300—uterine cancer	3.98e-06	6.65e-05	CbGpPWpGaD
Haloperidol—DRD1—Signaling Pathways—PIK3CA—uterine cancer	3.98e-06	6.64e-05	CbGpPWpGaD
Haloperidol—UGT1A9—Metabolism—AKT1—uterine cancer	3.96e-06	6.61e-05	CbGpPWpGaD
Haloperidol—CYP1A1—Metabolism—PTEN—uterine cancer	3.94e-06	6.58e-05	CbGpPWpGaD
Haloperidol—DRD3—Signaling Pathways—PIK3CA—uterine cancer	3.92e-06	6.55e-05	CbGpPWpGaD
Haloperidol—HTR2B—Signaling Pathways—HRAS—uterine cancer	3.9e-06	6.51e-05	CbGpPWpGaD
Haloperidol—DRD1—Signaling Pathways—TP53—uterine cancer	3.85e-06	6.42e-05	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—VEGFA—uterine cancer	3.84e-06	6.42e-05	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—NRAS—uterine cancer	3.8e-06	6.34e-05	CbGpPWpGaD
Haloperidol—DRD3—Signaling Pathways—TP53—uterine cancer	3.8e-06	6.34e-05	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—VEGFA—uterine cancer	3.78e-06	6.31e-05	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—VEGFA—uterine cancer	3.77e-06	6.3e-05	CbGpPWpGaD
Haloperidol—CYP1A1—Metabolism—EP300—uterine cancer	3.76e-06	6.28e-05	CbGpPWpGaD
Haloperidol—HTR1D—Signaling Pathways—AKT1—uterine cancer	3.74e-06	6.25e-05	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—NRAS—uterine cancer	3.74e-06	6.24e-05	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—NRAS—uterine cancer	3.73e-06	6.22e-05	CbGpPWpGaD
Haloperidol—DRD1—Signaling Pathways—HRAS—uterine cancer	3.68e-06	6.14e-05	CbGpPWpGaD
Haloperidol—HTR1B—Signaling Pathways—AKT1—uterine cancer	3.67e-06	6.12e-05	CbGpPWpGaD
Haloperidol—DRD3—Signaling Pathways—HRAS—uterine cancer	3.63e-06	6.06e-05	CbGpPWpGaD
Haloperidol—DRD4—Signaling Pathways—AKT1—uterine cancer	3.61e-06	6.02e-05	CbGpPWpGaD
Haloperidol—CYP3A4—Metabolism—MTHFR—uterine cancer	3.49e-06	5.82e-05	CbGpPWpGaD
Haloperidol—HTR2B—Signaling Pathways—AKT1—uterine cancer	3.44e-06	5.75e-05	CbGpPWpGaD
Haloperidol—CYP3A7—Metabolism—AKT1—uterine cancer	3.33e-06	5.56e-05	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—KRAS—uterine cancer	3.27e-06	5.46e-05	CbGpPWpGaD
Haloperidol—DRD1—Signaling Pathways—AKT1—uterine cancer	3.25e-06	5.42e-05	CbGpPWpGaD
Haloperidol—CYP2C19—Metabolism—PTEN—uterine cancer	3.23e-06	5.39e-05	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—KRAS—uterine cancer	3.22e-06	5.37e-05	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—KRAS—uterine cancer	3.21e-06	5.36e-05	CbGpPWpGaD
Haloperidol—DRD3—Signaling Pathways—AKT1—uterine cancer	3.21e-06	5.35e-05	CbGpPWpGaD
Haloperidol—ABCB1—Metabolism—PTEN—uterine cancer	3.15e-06	5.26e-05	CbGpPWpGaD
Haloperidol—CYP2C19—Metabolism—EP300—uterine cancer	3.08e-06	5.14e-05	CbGpPWpGaD
Haloperidol—ABCB1—Metabolism—EP300—uterine cancer	3e-06	5.02e-05	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—PIK3CA—uterine cancer	3e-06	5.01e-05	CbGpPWpGaD
Haloperidol—CYP2D6—Metabolism—PTEN—uterine cancer	2.97e-06	4.96e-05	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—PIK3CA—uterine cancer	2.95e-06	4.93e-05	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—PIK3CA—uterine cancer	2.95e-06	4.92e-05	CbGpPWpGaD
Haloperidol—CYP3A5—Metabolism—PIK3CA—uterine cancer	2.95e-06	4.92e-05	CbGpPWpGaD
Haloperidol—CYP2C9—Metabolism—PTEN—uterine cancer	2.94e-06	4.91e-05	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—TP53—uterine cancer	2.9e-06	4.85e-05	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—TP53—uterine cancer	2.86e-06	4.77e-05	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—TP53—uterine cancer	2.85e-06	4.76e-05	CbGpPWpGaD
Haloperidol—CYP2D6—Metabolism—EP300—uterine cancer	2.83e-06	4.73e-05	CbGpPWpGaD
Haloperidol—CYP2C9—Metabolism—EP300—uterine cancer	2.81e-06	4.69e-05	CbGpPWpGaD
Haloperidol—CYP1A1—Metabolism—PIK3CA—uterine cancer	2.78e-06	4.65e-05	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—HRAS—uterine cancer	2.78e-06	4.64e-05	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—HRAS—uterine cancer	2.73e-06	4.56e-05	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—HRAS—uterine cancer	2.73e-06	4.55e-05	CbGpPWpGaD
Haloperidol—CYP1A2—Metabolism—PTEN—uterine cancer	2.51e-06	4.2e-05	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—AKT1—uterine cancer	2.45e-06	4.09e-05	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—AKT1—uterine cancer	2.41e-06	4.03e-05	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—AKT1—uterine cancer	2.41e-06	4.02e-05	CbGpPWpGaD
Haloperidol—CYP3A5—Metabolism—AKT1—uterine cancer	2.41e-06	4.02e-05	CbGpPWpGaD
Haloperidol—CYP1A2—Metabolism—EP300—uterine cancer	2.4e-06	4e-05	CbGpPWpGaD
Haloperidol—CYP2C19—Metabolism—PIK3CA—uterine cancer	2.28e-06	3.8e-05	CbGpPWpGaD
Haloperidol—CYP1A1—Metabolism—AKT1—uterine cancer	2.27e-06	3.79e-05	CbGpPWpGaD
Haloperidol—ABCB1—Metabolism—PIK3CA—uterine cancer	2.22e-06	3.71e-05	CbGpPWpGaD
Haloperidol—CYP2D6—Metabolism—PIK3CA—uterine cancer	2.09e-06	3.5e-05	CbGpPWpGaD
Haloperidol—CYP2C9—Metabolism—PIK3CA—uterine cancer	2.08e-06	3.47e-05	CbGpPWpGaD
Haloperidol—CYP3A4—Metabolism—PTEN—uterine cancer	1.94e-06	3.24e-05	CbGpPWpGaD
Haloperidol—CYP2C19—Metabolism—AKT1—uterine cancer	1.86e-06	3.11e-05	CbGpPWpGaD
Haloperidol—CYP3A4—Metabolism—EP300—uterine cancer	1.85e-06	3.09e-05	CbGpPWpGaD
Haloperidol—ABCB1—Metabolism—AKT1—uterine cancer	1.82e-06	3.03e-05	CbGpPWpGaD
Haloperidol—CYP1A2—Metabolism—PIK3CA—uterine cancer	1.77e-06	2.96e-05	CbGpPWpGaD
Haloperidol—CYP2D6—Metabolism—AKT1—uterine cancer	1.71e-06	2.86e-05	CbGpPWpGaD
Haloperidol—CYP2C9—Metabolism—AKT1—uterine cancer	1.7e-06	2.83e-05	CbGpPWpGaD
Haloperidol—CYP1A2—Metabolism—AKT1—uterine cancer	1.45e-06	2.42e-05	CbGpPWpGaD
Haloperidol—CYP3A4—Metabolism—PIK3CA—uterine cancer	1.37e-06	2.29e-05	CbGpPWpGaD
Haloperidol—CYP3A4—Metabolism—AKT1—uterine cancer	1.12e-06	1.87e-05	CbGpPWpGaD
